Core Viewpoint - NorthStrive Fund II LP recommends that Bluejay Diagnostics' Board of Directors evaluate a strategic acquisition opportunity that could significantly enhance long-term shareholder value [1][4][20]. Group 1: Shareholder Engagement - NorthStrive Fund is a significant shareholder of Bluejay, as disclosed in a Schedule 13G filed with the U.S. Securities and Exchange Commission [2]. - The Fund expresses support for the Board and management's progress on the SYMON™ II program while encouraging pipeline expansion [3][8]. Group 2: Proposed Acquisition - The letter suggests that Bluejay consider acquiring a Phase-1-ready therapeutic asset targeting refractory chronic cough, a condition affecting millions and representing a market opportunity exceeding $10 billion annually [4][14]. - The proposed asset is a small-molecule inhibitor of fatty acid amide hydrolase (FAAH), designed to increase levels of anandamide, potentially desensitizing hyperactive sensory neurons responsible for the cough reflex [14][15]. Group 3: Clinical and Financial Considerations - NorthStrive Fund believes that adding a differentiated clinical-stage program could diversify development risk and introduce multiple clinical catalysts, enhancing long-term market valuation [4][5]. - Financing for the potential acquisition has been arranged through a public-company financing structure, which could strengthen Bluejay's capital position [5][19]. Group 4: Market Context and Differentiation - Recent interest from larger pharmaceutical companies in the refractory chronic cough space has increased, highlighted by GSK's $2 billion acquisition of BELLUS Health in 2023 [17]. - The proposed program's mechanism is distinct from existing chronic cough treatments, potentially reducing the risk of side effects associated with current therapies [18]. Group 5: Strategic Recommendations - The letter emphasizes the importance of evaluating opportunities to add clinical-stage programs with clear competitive advantages and compelling risk-adjusted upside [11]. - It also highlights the need for programs capable of generating meaningful clinical milestones within the next 12–24 months to enhance investor visibility and valuation [12][13].